BioNTech SE
BNTX
$89.27
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.32B | 3.53B | 3.13B | 2.97B | 2.98B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.32B | 3.53B | 3.13B | 2.97B | 2.98B |
| Cost of Revenue | 700.76M | 607.84M | 631.14M | 608.79M | 584.76M |
| Gross Profit | 2.62B | 2.92B | 2.49B | 2.36B | 2.39B |
| SG&A Expenses | 710.12M | 597.28M | 589.12M | 631.01M | 648.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 936.73M | 769.66M | 341.02M | 652.17M | 698.51M |
| Total Operating Expenses | 4.73B | 4.42B | 3.95B | 4.33B | 4.37B |
| Operating Income | -1.41B | -885.53M | -823.97M | -1.36B | -1.39B |
| Income Before Tax | -1.16B | -575.80M | -430.21M | -840.49M | -731.97M |
| Income Tax Expenses | 103.34M | 57.46M | -48.29M | -27.86M | -14.84M |
| Earnings from Continuing Operations | -1.26K | -633.26 | -381.92 | -812.62 | -717.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.26B | -633.26M | -381.92M | -812.62M | -717.13M |
| EBIT | -1.41B | -885.53M | -823.97M | -1.36B | -1.39B |
| EBITDA | -1.12B | -509.70M | -544.53M | -1.09B | -1.12B |
| EPS Basic | -5.23 | -2.63 | -1.58 | -3.38 | -2.99 |
| Normalized Basic EPS | -2.75 | -1.22 | -0.78 | -1.86 | -1.58 |
| EPS Diluted | -5.23 | -2.63 | -1.59 | -3.40 | -3.00 |
| Normalized Diluted EPS | -2.75 | -1.22 | -0.78 | -1.86 | -1.59 |
| Average Basic Shares Outstanding | 965.34M | 961.42M | 963.84M | 962.63M | 962.81M |
| Average Diluted Shares Outstanding | 965.34M | 961.42M | 966.82M | 965.61M | 965.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |